Press Releases

March 2 2012

The Biotechnology Industry Organization (BIO) announced today that it has integrated its...

February 9 2012

BIO President and CEO Jim Greenwood issued the following statement regarding the newly...

October 13 2011

BIO President and CEO Jim Greenwood released the following statement on the Obama...

October 7 2011

In a case brought against USDA’s Animal and Plant Health Inspection Service (APHIS), the...

September 9 2011

BIO President and CEO Jim Greenwood released the following statement on President Obama’...

June 29 2011

“Unleashing the Promise of Biotechnology: Advancing American Innovation to Cure Disease...

June 17 2008

As the BIO 2008 International Convention gets underway in San Diego this week, the Excellence...

May 7 2008

Major global issues, such as sustainable agriculture, industry stewardship and genetically...

July 25 2007

The Biotechnology Industry Organization (BIO) today launched a new program, Excellence Through...

January 24 2013
To ensure transparency and communication between patients and their treatment teams, BIO believes that certain safeguards should guide substitution policies for interchangeable biologics under state law as well.
October 4 2010
BIO policy recommends that BIO members anticipate, consider and develop approaches to help manage and mitigate any potential significant, unintentional processing, product functional or compositional negative effects in crop use or processing streams.
Comments are regarding conservation and stewardship requirements, matching payments, establishment costs and annual payments, disclosure of competitively sensitive information, invasiveness determination and review, consistency with existing FSA programs, corporations and publicly traded company participation, eligible materials, and algae.
June 6 2012
The report will be released at a Super Session, titled "International Leaders Share Their Worldview: Scientific American's Regional Bio-Innovation Scorecard."
March 2 2012
The Biotechnology Industry Organization (BIO) announced today that it has integrated its alliance development activities into one department as a means of expanding engagement opportunities with external groups that share a commitment to unleashing biotechnology’s capability to benefit patients and consumers.
February 9 2012
BIO President and CEO Jim Greenwood issued the following statement regarding the newly released U.S. Food and Drug Administration (FDA) guidance for the review and approval of biosimilars.
October 13 2011
BIO President and CEO Jim Greenwood released the following statement on the Obama Administration's intent to create a National Bioeconomy Blueprint.
October 7 2011
In a case brought against USDA’s Animal and Plant Health Inspection Service (APHIS), the U.S. District Court for the Southern District of Florida has denied the plaintiff’s motion for summary judgment and granted the summary judgment motions for the government, ArborGen, and BIO.